奥拉西坦改善脑梗死患者认知功能障碍的疗效观察

Clinical Efficacy of Oxiracetam on Cognitive Impairment of Cerebral Infarction Patients

目的:探讨奥拉西坦治疗脑梗死患者认知障碍的临床疗效及安全性。方法:脑梗死患者100例随机分为对照组和奥拉西坦组各50例。2组均给予常规治疗,奥拉西坦组加用奥拉西坦。比较2组患者治疗后的MMSE、ADL等量表评分、临床疗效等。结果:治疗后奥拉西坦组的MMSE评分高于对照组(P<0.05),ADL评分低于对照组(P<0.05)。奥拉西坦组的总有效率为92.0%,高于对照组的74.0%(P<0.05)。结论:奥拉西坦改善急性脑梗死患者的认知功能障碍安全有效。

Objective： To explore clinical effect and safety of oxiracetam on cognitive impairment of cerebral infarction patients. Methods： Total 100 cerebral infarction patients with cognitive impairment were randomly divided into groups of control and Oxiracetam with 50 cases in each group. The two groups were given routine treatment, and the Oxiracetam group was added oxiracetam treatment. Scores of MMSE, ADL and clinical effects were compared between the two groups after treatment. Results： After treatment, the patients in the Oxiracetam group showed a significant higher MMSE score and lower ADL score than those in the control group （P〈0.05）. The total effective rate of the Oxiracetam group was 92.0%, obviously higher than that in the control group （74.0%, P〈0.05）. Conclusion： Oxiracetam is effective and safe to attenuate cognitive impairment of cerebral infarction patients.